Antabio Funding: $55M Raised, Series B (2023)

Antabio funding overview

Antabio is based in Labèģı, France. Antabio has raised $55M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in December 2023. The round record for Antabio runs through 2023; nothing later has been disclosed. Investors on record include BNP Paribas Développement, Turenne Capital, IRDI Capital Investissement, Christophe Ricard. 4 distinct backers are named across the disclosed rounds.

Antabio at a glance

Total raised: $55M
Latest round: Series B
Latest round date: December 2023
Headquarters: Labèģı, France
Notable investors: BNP Paribas Développement, Turenne Capital, IRDI Capital Investissement, Christophe Ricard

Frequently asked about Antabio funding

How much has Antabio raised?: Antabio has raised $55M in total disclosed funding across the rounds on record.
Who has invested in Antabio?: BNP Paribas Développement, Turenne Capital, IRDI Capital Investissement, Christophe Ricard are named among the investors backing Antabio.
What was the latest Antabio funding round?: The most recent disclosed round is a Series B, announced in December 2023.
Where is Antabio based?: Antabio is based in Labèģı, France.
When did Antabio last raise?: The last disclosed Antabio round closed in December 2023 at Series B.

Totals shown for Antabio aggregate every disclosed round on file. To see how that compares, browse the companies in Labèģı and the investors behind them below.

Antabio Funding: $55M Raised, Series B (2023)

Antabio funding overview

Antabio at a glance

Frequently asked about Antabio funding

Companies related to Antabio (38)

Browse related funding lists (4)